ACROBiosystems, a company dedicated to being a cornerstone of the global biopharmaceutical and healthcare industries, has entered into a research collaboration with SeromYx Systems, specializing in advanced immunology technologies. The partnership aims to comprehensively profile the function of approved anti-CD20 monoclonal antibodies (mAbs).

The collaboration leverages ACROBiosystems' recombinant human full-length CD20 virus-like particles (VLPs) and SeromYx's biophysical and cellular Fc-effector function platform to unlock new breakthrough understanding of the potential drivers of therapeutic safety and efficacy of anti-CD20 mAbs.

CD20, a critical target for treating B-cell malignancies and autoimmune diseases, is selectively expressed on B-cells, allowing for effective B-cell depletion while preserving long-term immune memory. The study compared the biophysical binding and immune effector functions of Rituximab (RTX), Ofatumumab (OFA), and Obinutuzumab (OBZ), providing a detailed analysis of their mechanisms of action.

Robust binding profiles and distinct Fc-effector functions of the anti-CD20 mAbs were observed throughout the study. Notably, the collaboration discovered new Fc-effector functions, including antibody-dependent neutrophil and eosinophil phagocytosis activities. These findings broaden the understanding of how these mAbs engage with immune cells, potentially influencing their efficacy in various clinical settings.

"This collaborative study together with SeromYx represents a significant step in exploring the expansive applications of our human CD20 full-length VLP. We are excited to see how our full-length transmembrane proteins contribute to a greater understanding of antibody drug efficacy, driving forward innovations in the field of immunology and more," said John Miao, Senior VP at ACROBiosystems.

"This study not only reinforces the importance of comprehensive Fc effector profiling as a critical tool for all mAbs in development, ensuring a deeper understanding of safety and efficacy mechanisms, but also has implications for the development of new anti-CD20 mAbs," said Lenny Moise, VP of Research, at SeromYx.